NEW YORK (GenomeWeb) – Vermillion said today that Medi-Cal, California's Medicaid program, now supports the company's OVA1 ovarian cancer test in its medical policy guidelines.

According to Vermillion, Medi-Cal covers more than 12.6 million lives, or roughly a third of the covered lives in California.

OVA1 measures levels of five proteins in patient blood and is intended for triaging patients with ovarian adnexal masses as part of preoperative evaluations to determine the likelihood that a mass is cancerous.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.